206 / 1498
Phase II trial design
BV in early favorable HL
* a) large mediastinal mass b) extranodal disease c) elevated ESR d) ≥3 nodal areas
#
to be discussed: 1.8 mg/kg every 3 weeks or 1.2 mg/kg every 2 weeks
cHL in CS I/II without RF*
Age 18-75
20 Gy IS-RT
4 x BV
#
Strategy A: Reducing
Chemotherapy
4 x BV
#
2 x AVD
Strategy B: Replacing
Radiotherapy